Ligusticum cycloprolactam
Ligusticum cycloprolactam is a potent, orally active, and CNS-penetrant TLR4/NF-κB inhibitor, exhibiting anti-inflammatory and neuroprotective activity. Ligusticum cycloprolactam reduces FPR1 expression, inhibits NLRP3 inflammasome, TLR4/NF-κB, hepatic MAPK and TGF-β signaling, and selectively activates hepatic FXR. Ligusticum cycloprolactam attenuates pro-inflammatory mediator production, enhances anti-inflammatory cytokine secretion, regulates renal uric acid transporters, and preserves intestinal microbiota composition. Ligusticum cycloprolactam can be used for the research of ischemic stroke, hyperuricemic nephropathy, neuroinflammation, and metabolic dysfunction-associated fatty liver disease.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 2283387-37-9
- Formel: C15H21NO2
- Molecular Weight:247.33
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
IC50 & Target
[1]|
TLR4 |
IL-6 |
IL-1b |
IL-1β |
NLRP3 |
In Vitro
Ligusticum cycloprolactam (LIGc) (2.5-10 μM; 2 h) dose-dependently suppresses LPS (HY-D1056)-induced pro-inflammatory mediator (NO, TNF-α, IL-1β) production and promotes anti-inflammatory cytokine (IL-4, IL-10) secretion in RAW264.7 mouse macrophages[1].
Ligusticum cycloprolactam (2.5-10 μM; 2 h) dose-dependently reduces LPS-induced pro-inflammatory protein (CD86, iNOS, COX-2) expression and increases anti-inflammatory protein (CD206) expression in RAW264.7 mouse macrophages[1].
Ligusticum cycloprolactam (10 μM; 2 h) inhibits LPS-induced pro-inflammatory gene (cd86, Nos2) expression in RAW264.7 mouse macrophages[1].
Ligusticum cycloprolactam (LIGc) (10 μM; 2 h) reduces LPS-induced pro-inflammatory CD86 marker expression in primary mouse microglia[1].
Ligusticum cycloprolactam (10 μM; 2 h) modulates the transcriptional profile of LPS-stimulated RAW264.7 mouse macrophages, with significant downregulation of the pro-inflammatory Fpr1 gene and enrichment of anti-inflammatory signaling pathways[1].
Ligusticum cycloprolactam (10 μM; 2 h) inhibits LPS-induced FPR1 protein expression in RAW264.7 mouse macrophages[1].
Ligusticum cycloprolactam (10 μM; 2 h) inhibits LPS-induced NLRP3 protein expression in RAW264.7 mouse macrophages and primary mouse microglia[1].
Ligusticum cycloprolactam (10 μM; 2 h) exerts anti-inflammatory effects in LPS-stimulated RAW264.7 mouse macrophages and primary mouse microglia by downregulating the FPR1/NLRP3 signaling axis, as FPR1 overexpression reverses these effects[1].
Ligusticum cycloprolactam (20-80 μM; 36 h) ameliorates uric acid (HY-B2130)-induced injury in NRK-52E cells by suppressing the TLR4/NF-κB signaling pathway, reducing inflammatory and fibrotic responses[2].
Ligusticum cycloprolactam (2.5-40 μM; 24 h) has no cytotoxic effect on BV2 microglia cells at concentrations up to 20 μM for 24 h, but reduces cell viability at 40 μM[3].
Ligusticum cycloprolactam (5-20 μM; 1 h) dose-dependently reduces LPS-induced NO production in BV2 microglia cells, with the strongest inhibition at 10 μM[3].
Ligusticum cycloprolactam (5-20 μM; 1 h) dose-dependently reduces LPS-induced TNF-α and IL-1β secretion in BV2 microglia cells[3].
Ligusticum cycloprolactam (10 μM; 1 h) inhibits LPS-induced activation of the NF-κB pathway in BV2 microglia cells by reducing phosphorylation of IκBα, IKKα+β, and NF-κB p65[3].
Ligusticum cycloprolactam (10 μM; 1 h) protects HT22 hippocampal neuron cells from neurotoxicity induced by conditioned medium from LPS-activated BV2 microglia cells, restoring HT22 cell viability[3].
Ligusticum cycloprolactam (10 μM; 1 h) attenuates LPS-activated BV2 microglia-induced apoptosis in HT22 hippocampal neuron cells by restoring the Bcl2/Bax ratio and reducing BID and CytC expression[3].
Ligusticum cycloprolactam (LIGc) directly binds to purified FXR protein in a cell-free molecular docking assay[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:LPS-stimulated RAW264.7 mouse macrophages
-
Concentration:2.5; 5; 10 μM
-
Incubation Time:2 h
-
Result:Dose-dependently inhibited LPS-induced production of NO, TNF-α, and IL-1β.
Enhanced secretion of IL-4 and IL-10, with optimal effects observed at 10 μM.
All changes were statistically significant compared to the LPS-only group.
-
Cell Line:LPS-stimulated RAW264.7 mouse macrophages
-
Concentration:2.5; 5; 10 μM
-
Incubation Time:2 h
-
Result:Dose-dependently attenuated LPS-induced upregulation of CD86, iNOS, and COX-2 protein expression, while increasing CD206 protein expression, with significant differences compared to the LPS-only group at all tested concentrations.
-
Cell Line:LPS-stimulated RAW264.7 mouse macrophages
-
Concentration:10 μM (2 h pretreatment); 100 ng/mL LPS (12 h co-treatment)
-
Incubation Time:2 h (pretreatment); 12 h (co-treatment)
-
Result:Significantly suppressed LPS-induced FPR1 protein expression, compared to the LPS-only group.
-
Cell Line:NRK-52E cells
-
Concentration:20; 40; 80 μM
-
Incubation Time:36 h
-
Result:Effectively reversed the uric acid-induced
upregulation of transcription levels for inflammatory and fibrotic markers such as Nlrp3, IL-1b, Fn1 and Tgfb1.
Decreased the levels of KIM-1, NLRP3, IL-1β, VCAM1, FN and α-SMA proteins while enhancing E-cadherin protein expres-
sion.
-
Cell Line:LPS-stimulated mouse BV2 microglia cells
-
Concentration:5; 10; 20 μM
-
Incubation Time:1 h
-
Result:Significantly attenuated LPS-induced increase in TNF-α and IL-1β secretion at 5, 10, and 20 μM.
Exhibited the most potent inhibitory effect on both cytokines at 10 μM.
-
Cell Line:BV2 microglia cells
-
Concentration:2.5; 5; 10; 20; 40 μM
-
Incubation Time:24 h
-
Result:Showed cytotoxic effect on BV2 microglia cells at concentrations up to 20 μM.
Reduces cell viability at 40 μM.
In Vivo
Ligusticum cycloprolactam (20 and 60 mg/kg; i.g.; at 1, 24, and 48 hours post-I/R) dose-dependently reduces cerebral infarction volume and improves neurological function in tMCAO mice[1].
Ligusticum cycloprolactam (20-80 mg/kg; i.g.; daily; 3 weeks) ameliorates hyperuricemic nephropathy in mice by reducing uric acid levels, renal inflammation, and fibrosis via inhibition of the TLR4/NF-κB pathway[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Adult male Kunming mice (8-10 weeks old, 24 g)[1]
-
Dosage:20; 60 mg/kg
-
Administration:p.o.; daily; 4 days
-
Result:Improved LPS-induced alterations in open field metrics including increased distance covered, distance in center, time in center, and activity time, alongside decreased time in corner and rest time.
Reduced the number of Iba1+CD86+ pro-inflammatory microglia/macrophages in the cerebral cortex.
Suppressed cerebral cortex levels of pro-inflammatory markers TNF-α, IL-1β, CD86, iNOS, and COX-2, while increasing anti-inflammatory markers IL-4, IL-10, and CD206 at 20 mg/kg dose.
Produced similar, more pronounced effects at 60 mg/kg dose, including significant suppression of FPR1 and NLRP3 protein expression in the cerebral cortex.
-
Animal Model:Adult male Kunming mice (8-10 weeks old, 24 g) tMCAO model[1]
-
Dosage:20; 60 mg/kg
-
Administration:i.g.; at 1, 24, and 48 hours post-I/R
-
Result:Reduced cerebral infarction volume in a dose-dependent manner, with the 60 mg/kg dose producing a larger reduction.
Improved neurological function significantly, as shown by lower Longa scores, reduced rightward turning tendency in the corner test, and increased use of the affected forelimb in the cylinder test.
Decreased the number of Iba1+CD86+ pro-inflammatory microglia/macrophages in the infarct-surrounding cerebral cortex, suppressed pro-inflammatory markers TNF-α, IL-1β, CD86, iNOS, and COX-2, and increased anti-inflammatory markers IL-4, IL-10, and CD206.
Significantly reduced FPR1 and NLRP3 protein expression in the cerebral cortex at 60 mg/kg dose.
-
Animal Model:Male C57BL/6J ( 8-week-old) with hyperuricemic nephropathy induced by hypoxanthine and potassium oxonate[2]
-
Dosage:20, 40, 80 mg/kg
-
Administration:i.g.; daily; 3 weeks
-
Result:Reduced elevated serum uric acid levels and liver xanthine oxidase (XOD) activity.
Lowered kidney index, serum creatinine, blood urea nitrogen, and 24-hour albuminuria.
Ameliorated renal histological damage.
Dose-dependently reduced macrophage infiltration (F4/80-positive staining) and downregulated mRNA/protein expression of inflammatory markers (F4/80, Icam-1, IL-6, Ccl2, Nlrp3, IL-1b, MCP-1, NLRP3, IL-1β).
Decreased renal collagen deposition and downregulated fibrosis markers (Fn1, Col4a1, Tgfb1, Timp1, FN, α-SMA) while increasing E-cadherin.
Reversed dysregulation of renal uric acid transporters (upregulated Abcg2, Oat3, Oct2 mRNA and OAT1 protein.
Downregulated Glut9 mRNA and URAT1, GLUT9 protein.
Inhibited TLR4/NF-κB signaling.
Chemical Information
-
CAS. Nr. 2283387-37-9
-
Molecular Weight 247.33
-
Formel C15H21NO2
-
SMILES
O=C1C2=C(C(N1C3CC3)(CCCC)O)CCC=C2
-
Structure Classification
-
Initial Source
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Research Protocol for Microbiome Analysis
Microbiome analysis characterizes microbial communities in biological or environmental samples by measuring community composition, diversity, taxonomic structure, functional potential, and associations with host or environmental phenotypes. 16S rRNA gene amplicon sequencing is commonly used for bacterial and archaeal taxonomic profiling, while shotgun metagenomics provides higher taxonomic resolution and direct functional information, including microbial genes, pathways, viruses, fungi, and antimicrobial-resistance genes when sequencing depth and host-DNA contamination are adequately controlled. Microbiome results are strongly affected by sample collection, storage, DNA extraction, contamination, sequencing method, reference database, and bioinformatic pipeline; therefore, standardized protocols, negative controls, mock communities, and transparent analysis workflows are required. Unresolved issues include low-biomass contamination, compositional-data bias, inconsistent species-level c
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Research Protocol for Neurological Diseases
PINK1/Parkin-mediated mitophagy pathway is a mitochondrial quality-control signaling axis in which mitochondrial depolarization stabilizes PINK1 on damaged mitochondria, activates Parkin recruitment and E3 ubiquitin ligase activity, promotes ubiquitination of outer mitochondrial membrane proteins, recruits selective autophagy adaptors, and drives lysosomal degradation of damaged mitochondria. In neurological disease research, this pathway is experimentally important because neurons, especially dopaminergic neurons, are highly dependent on mitochondrial integrity, and defective mitochondrial turnover can lead to mitochondrial dysfunction, oxidative stress, impaired neuronal survival, α-synuclein accumulation, and neuroinflammatory damage-associated signals. The genetic disease link is strongest in Parkinson’s disease because mutations in PRKN/parkin cause autosomal recessive juvenile parkinsonism, mutations in PINK1 cause hereditary early-onset Parkinson’s disease, and Drosophila studie
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
Reinheit & Dokumentation
Verweise
[1]. Gao J, et al. A Novel Compound Ligusticum Cycloprolactam Alleviates Neuroinflammation After Ischemic Stroke via the FPR1/NLRP3 Signaling Axis. CNS Neurosci Ther. 2024;30(12):e70158. [Content Brief]
[2]. Chen Z, et al. Ligusticum cycloprolactam ameliorates hyperuricemic nephropathy through inhibition of TLR4/NF-κB signaling. J Nutr Biochem. 2025;139:109864. [Content Brief]
[3]. Gao J, et al. Mechanism of ligusticum cycloprolactam against neuroinflammation based on network pharmacology and experimental verification. Clin Exp Pharmacol Physiol. 2023;50(8):647-663. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Keywords
- Ligusticum cycloprolactam
- 2283387-37-9
- Toll-like Receptor (TLR)
- NF-κB
- Collagen
- Interleukin Related
- Cadherin
- NOD-like Receptor (NLR)
- TGF-β Receptor
- FXR
- Apoptosis
- TGF-β signaling
- NLRP3 inflammasome
- TLR4/NF-κB
- primary mouse microglia
- FPR1
- BV2 microglia cells
- NRK-52E cells
- MAPK
- RAW264.7 mouse macrophages
- Inhibitor
- inhibitor
- inhibit